The frequently aberrant DNA methylation of SDC2 and TFPI2 makes them promise biomarkers for the early detection of CRC, and a few testing kits based on the two targets were also developed [19, 21–24]. The gene discussed is TFPI2; the disease is colorectal carcinoma.